Pharmacokinetics of Antiretroviral Agents in HIV-1 Infected Pregnant Women
Completed · Phase 1
Conditions studied: HIV Infection
In brief
This study will determine if blood levels of anti-HIV drugs in pregnant women change at different stages of pregnancy and if these changes require dosage adjustments in order to maintain adequate drug levels during pregnancy. Anti-HIV medications are recommended for HIV-infected women during pregnancy not only to treat their infection, but also to reduce the chance of passing the virus to the baby during pregnancy. Changes in the body that occur during pregnancy may affect how the body uses and eliminates these drugs, reducing their levels during pregnancy. Pregnant women 18 years of age or older who are infected with HIV may be eligible for this study. Candidates will have a medical history and physical examination, pregnancy test and blood tests. Participants will come to the NIH Clinical Center once every 6 to 12 weeks until around their 34th week (8 months) of pregnancy and then again at least 1 month after the birth of the baby to have blood drawn. A catheter (thin plastic tube) will be placed in a vein to avoid multiple needle sticks for blood sampling during the day. The first sample will be collected before the patient takes the morning doses of anti-HIV medicines and additional samples will be drawn at 1, 2, 4, 8 and 12 hours after taking the medication. A urine sample will also be collected at each visit.
Key facts
- Study ID
- NCT00006320
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 20
- Starts
- 2000-09-01
- Expected to finish
- 2004-07-01
- Last updated by the study team
- 2008-03-04
Who can join
Age: any. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- HIV-1 positive as documented by ELISA and confirmed by Western Blot test
- Positive urine pregnancy test or positive serum Beta-HCG
- Age greater than or equal to 18 years
- At least 14-week gestation at the time of screening as estimated by the subject's obstetrician
- Having a normal pregnancy per the subject's obstetrician's assessment
- Maintained on or to be started on a HAART regimen containing at least three antiretroviral agents
- Hgb greater than or equal to 10 gm/dL, platelet greater than or equal to 100,000/mL, PT less than or equal to 14.0 sec
- S.Cr. less than 2.0 mg/dL, ALT and AST less than or equal to 2 times the upper limit of normal
You may not qualify if…
- Receiving treatment for an active HIV-related opportunistic infection
- Significant medical conditions such as diabetes (including gestational diabetes), hypertension, coronary artery disease, seizure disorder, asthma, or other medical conditions that in the investigators' opinion will not be safe for the subject to participate in this study
- History of significant obstetric complications during prior pregnancy(ies)
- Concurrent illicit drug or alcohol abuse
- Not receiving ongoing medical care for HIV infection and pregnancy
- Efavirenz as part of HAART regimen
- Combination of didanosine and stavudine as part of HAART regimen
- Presence of persistent diarrhea or history of malabsorption that will interfere with the subject's ability to absorb the antiretroviral drugs
- Refusal to allow the investigators to obtain medical records from her HIV care provider and her obstetricians during the course of the study
- Unable to obtain venous access for blood draw
- Refusal to agree to allow the specimen to be stored for future research
Where it is running
- National Institute of Allergy and Infectious Diseases (NIAID) — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.